News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
858,288 Results
Type
Article (87413)
Company Profile (739)
Press Release (770118)
Multimedia
Podcasts (197)
Webinars (28)
Section
Business (232768)
Career Advice (4143)
Deals (39873)
Drug Delivery (144)
Drug Development (91175)
Employer Resources (205)
FDA (18253)
Job Trends (17422)
News (396850)
Policy (39843)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3002)
Academic (1)
Accelerated approval (31)
Adcomms (30)
Allergies (120)
Alliances (56794)
ALS (153)
Alzheimer's disease (1749)
Antibody-drug conjugate (ADC) (312)
Approvals (18366)
Artificial intelligence (467)
Autoimmune disease (155)
Automation (31)
Bankruptcy (402)
Best Places to Work (12512)
BIOSECURE Act (23)
Biosimilars (204)
Biotechnology (457)
Bladder cancer (145)
Brain cancer (52)
Breast cancer (538)
Cancer (4276)
Cardiovascular disease (302)
Career advice (3568)
Career pathing (41)
CAR-T (289)
CDC (36)
Celiac Disease (1)
Cell therapy (761)
Cervical cancer (29)
Clinical research (76104)
Collaboration (1604)
Company closure (4)
Compensation (990)
Complete response letters (64)
COVID-19 (2927)
CRISPR (85)
C-suite (732)
Cystic fibrosis (143)
Data (5410)
Decentralized trials (2)
Denatured (73)
Depression (114)
Diabetes (340)
Diagnostics (6976)
Digital health (23)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (251)
Drug pricing (161)
Drug shortages (19)
Duchenne muscular dystrophy (198)
Earnings (97997)
Editorial (57)
Employer branding (25)
Employer resources (173)
Events (132801)
Executive appointments (824)
FDA (20617)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (24)
Funding (1269)
Gene editing (183)
Generative AI (46)
Gene therapy (601)
GLP-1 (931)
Government (5323)
Grass and pollen (4)
Guidances (276)
Healthcare (20777)
HIV (43)
Huntington's disease (46)
IgA nephropathy (79)
Immunology and inflammation (267)
Immuno-oncology (58)
Indications (80)
Infectious disease (3146)
Inflammatory bowel disease (203)
Inflation Reduction Act (14)
Influenza (95)
Intellectual property (198)
Interviews (816)
IPO (17808)
IRA (45)
Job creations (5198)
Job search strategy (2866)
JPM (66)
Kidney cancer (16)
Labor market (92)
Layoffs (639)
Leadership (37)
Legal (10091)
Liver cancer (87)
Longevity (13)
Lung cancer (582)
Lymphoma (332)
Machine learning (41)
Management (66)
Manufacturing (714)
MASH (159)
Medical device (14427)
Medtech (14457)
Mergers & acquisitions (22742)
Metabolic disorders (1062)
Multiple sclerosis (149)
NASH (22)
Neurodegenerative disease (327)
Neuropsychiatric disorders (79)
Neuroscience (2891)
Neurotech (1)
NextGen: Class of 2026 (7686)
Non-profit (5079)
Now hiring (65)
Obesity (520)
Opinion (325)
Ovarian cancer (150)
Pain (153)
Pancreatic cancer (170)
Parkinson's disease (260)
Partnered (33)
Patents (394)
Patient recruitment (414)
Peanut (56)
People (66277)
Pharmaceutical (133)
Pharmacy benefit managers (20)
Phase 1 (23596)
Phase 2 (33120)
Phase 3 (24814)
Pipeline (4284)
Policy (283)
Postmarket research (3544)
Preclinical (10586)
Press Release (72)
Prostate cancer (203)
Psychedelics (51)
Radiopharmaceuticals (278)
Rare diseases (792)
Real estate (7422)
Recruiting (80)
Regulatory (28228)
Reports (64)
Research institute (2695)
Resumes & cover letters (651)
Rett syndrome (21)
RNA editing (21)
RSV (63)
Schizophrenia (139)
Series A (224)
Series B (160)
Service/supplier (25)
Sickle cell disease (85)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (47)
Startups (4323)
State (2)
Stomach cancer (14)
Supply chain (74)
Tariffs (76)
The Weekly (122)
Vaccines (998)
Venture capital (91)
Weight loss (338)
Women's health (71)
Worklife (22)
Date
Last 7 days (472)
Last 30 days (1733)
Last 365 days (25244)
2026 (2379)
2025 (25555)
2024 (34036)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1279)
Alabama (85)
Alaska (6)
Arizona (288)
Arkansas (8)
Asia (51124)
Australia (9002)
California (9719)
Canada (2475)
China (1058)
Colorado (306)
Connecticut (389)
Delaware (296)
Europe (116901)
Florida (1256)
Georgia (253)
Hawaii (4)
Idaho (65)
Illinois (653)
India (56)
Indiana (445)
Iowa (21)
Japan (338)
Kansas (133)
Kentucky (25)
Louisiana (14)
Maine (59)
Maryland (1256)
Massachusetts (7303)
Michigan (244)
Minnesota (452)
Mississippi (5)
Missouri (78)
Montana (28)
Nebraska (29)
Nevada (106)
New Hampshire (57)
New Jersey (2549)
New Mexico (29)
New York (2550)
North Carolina (1410)
North Dakota (9)
Northern California (4770)
Ohio (257)
Oklahoma (18)
Oregon (51)
Pennsylvania (1870)
Puerto Rico (22)
Rhode Island (33)
South America (1658)
South Carolina (13)
South Dakota (1)
Southern California (3750)
Tennessee (58)
Texas (1358)
United States (33783)
Utah (209)
Vermont (1)
Virginia (168)
Washington D.C. (54)
Washington State (820)
West Virginia (2)
Wisconsin (82)
858,288 Results for "tr1x bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103
February 5, 2026
·
5 min read
Press Releases
Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing
October 15, 2025
·
4 min read
Press Releases
Tr1X Announces FDA Clearance of IND Application for TRX103, an Allogeneic Engineered Tr1 Treg Cell Therapy for Treatment-Refractory Crohn’s Disease
Tr1X Plans to Initiate a Phase 1/2a study and Dose the First Patient by the End of 2024
August 7, 2024
·
3 min read
Press Releases
Tr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive Chairman
March 31, 2025
·
3 min read
Press Releases
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease
April 4, 2025
·
3 min read
Press Releases
Tr1X to Participate at Upcoming Healthcare Investment Conferences
September 13, 2024
·
1 min read
Biotech Beach
Tr1X Announces FDA Clearance of First Investigational New Drug Application for TRX103, an Allogeneic Regulatory T-Cell Therapy to Treat Autoimmune Diseases
Tr1X, Inc. today announced the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application for TRX103 for the prevention of Graft versus Host Disease (GvHD) in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT).
April 10, 2024
·
4 min read
Mergers & acquisitions
How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio
Regulatory documents show how 89bio’s board pushed Roche hard for a deal valued at $20 per share in upfront and milestone payments.
October 2, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
January 27, 2026
·
2 min read
RNA editing
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop partnerships, pitch the potential of its new AATD program and find more money to keep the dream alive.
January 16, 2026
·
3 min read
·
Dan Samorodnitsky
1 of 85,829
Next
